Alivus Life Sciences posts Q1 FY27 earnings call audio online
Alivus Life Sciences Limited has published the audio recording of its Q1 FY27 earnings call on its website, as mandated by SEBI regulations. The call, held on July 31, 2026, discussed the company’s record net profit of ₹1,601 million and expanded EBITDA margins. Investors can access the recording via the provided link for detailed insights into the financial performance and strategic initiatives.
*this image is generated using AI for illustrative purposes only.
Alivus Life Sciences Limited has made the audio recording of its Q1 FY27 earnings call available to investors, following the conference held on July 31, 2026. The company uploaded the recording to its official website to ensure transparency and accessibility for stakeholders, in adherence to regulatory disclosure norms. This procedural step complements the financial results announced earlier, which reported a record net profit of ₹1,601 million for the quarter ended June 30, 2026.
The upload was confirmed via a letter addressed to the Department of Corporate Services at BSE Ltd. and the Manager – Listing at National Stock Exchange of India Ltd., citing Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Rudalf Corriea, Company Secretary & Compliance Officer, signed off on the communication on July 31, 2026, directing investors to the specific URL for access.
Regulatory Compliance and Access
The audio file is hosted at the company’s investor relations portal, providing detailed insights into management’s commentary on the Q1FY27 performance. The results highlighted a 31.8% year-on-year increase in profit after tax (PAT) and an expansion in EBITDA margins to 33.06% from 28.64%. The earnings call discussion likely covered these operational highlights, including the robust growth in the non-Generic Pharmaceutical Ingredient (non-GPL) portfolio, which grew 26.5% year-on-year.
Investors can access the recording directly through the provided link: https://alivus.b-cdn.net/alivus_pdfs/investors/financials/reports_presentation/10044984.mp3 . This ensures that all market participants have equal access to the management’s perspective on the financial health and future outlook of the company.
Financial Context
The availability of the earnings call audio adds depth to the previously reported financial figures. Key metrics from Q1FY27 include:
| Metric | Value | YoY Change |
|---|---|---|
| Net Profit (PAT) | ₹1,601 million | +31.8% |
| Revenue from Operations | ₹6,404 million | +6.4% |
| EBITDA | ₹2.1 billion | — |
| EBITDA Margin | 33.06% | Expanded from 28.64% |
The company’s strong cash position of ₹8,802 million and free cash flow generation of ₹901 million during the quarter further underscore its financial stability. The earnings call serves as a critical channel for addressing investor queries regarding capacity expansion plans, including the Solapur, Ankleshwar, and Dahej facilities, and their expected completion timelines in FY27.
Historical Stock Returns for Alivus Life Sciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.30% | -3.30% | +22.45% | +52.60% | +39.01% | +101.74% |
How will the upcoming completion of capacity expansions in Solapur, Ankleshwar, and Dahej impact Alivus's revenue mix and margin profile in FY27?
What specific growth drivers are expected to sustain the momentum in the non-GPL portfolio beyond the current 26.5% year-on-year increase?
Given the strong cash position of ₹8,802 million, what is management's strategy for capital allocation between debt reduction, M&A, and further capacity expansion?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
